EUVIMEDEUVIMED entdecken
Crossref

Real-world evaluation of anti-VEGF therapy in diabetic macular edema: The role of macular ischemia and OCT biomarkers BOSPHORUS DME study group report no: 14

Bengi Demirayak iD, Abdullah Özkaya iD, İsmail Umut Onur iD, Murat Arıcı, Anıl Korkmaz iD, Ece Özal iD, Serhat Ermiş iD, Şerife Çiloğlu Hayat iD, Murat Karapapak iD, Sadık Altan Özal iD, Nihat Sayın iD, Mehmet Erdoğan und 11 weitere

European Journal of Ophthalmology · 24.07.2026

DOI: 10.1177/11206721261471302 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Ophthalmology, online erschienen am 24.07.2026. Verfasst von Bengi Demirayak und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University of Health Sciences, Bakırköy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To compare the anatomical and functional outcomes of DME treatment with anti-VEGF between patients with and without macular ischemia and investigate the association between OCT biomarkers and macular ischemia.

Methods

Retrospective, multicenter, real-world analysis. Based on FFA before treatment, patients were divided into two groups: those with macular ischemia and those without macular ischemia. BCVA, CMT at 0, 6, and 12 months and treatment burden were recorded. Cyst patterns, EZ and/or ELM status, DRIL, hyperreflective foci, and presence of subretinal fluid were evaluated at every visit in OCT.

Results

A total of 1004 eyes from 770 patients were included. Macular ischemia was detected in 238 eyes (23.7%). Baseline BCVA was significantly lower in the ischemic group (0.81 ± 0.53 logMAR vs. 0.55 ± 0.39 logMAR, p = 0.0001). After adjustment for baseline covariates, ischemic eyes demonstrated longitudinal BCVA improvement at months 6 and 12 despite persistently lower overall vision levels. CMT significantly decreased over time in both groups without significant differences in anatomical response. Treatment burden was comparable between groups. Disorganization of retinal inner layers, hyperreflective foci, and vitreomacular interface abnormalities were significantly associated with macular ischemia.

Conclusion

In real-world settings, eyes with macular ischemia showed meaningful functional and anatomical improvement after anti-VEGF therapy in DME, despite worse visual acuity throughout follow-up. Macular ischemia was associated with poorer final visual outcomes but did not preclude treatment response.

Schlagwörter

Stichwörter der Autor:innen

Diabetic macular edema < RETINAdiabetic retinopathy < RETINApractice management < SOCIOECONOMICS AND EDUCATION IN MEDICINE/OPHTHALMOLOGYretina - medical therapies < RETINAtechniques of retinal examination < RETINA

Autor:innen und Institutionen

  • Department of Ophthalmology, University of Health Sciences, Bakırköy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey.
  • Department of Ophthalmology, Şişli Memorial Hospital, Istanbul, Turkey.
  • Department of Ophthalmology, Namik Kemal University Medical School, Tekirdağ, Turkey.
  • Department of Ophthalmology, University of Health Sciences, Beyoglu Eye Training and Research Hospital, Istanbul, Turkey.
  • Department of Ophthalmology, Basaksehir Cam ve Sakura City Hospital, Istanbul, Turkey.
  • Department of Ophthalmology, University of Health Sciences, Kanuni Sultan Süleyman Training and Research Hospital, Istanbul, Turkey.

ORCID-Profile: Bengi Demirayak, Abdullah Özkaya, İsmail Umut Onur, Anıl Korkmaz, Ece Özal, Serhat Ermiş, Şerife Çiloğlu Hayat, Murat Karapapak, Sadık Altan Özal, Nihat Sayın, İbrahim Koçak, Akin Çakır, Gamze Karataş, Dilan Yıldız, Ecem Önder Tokuç, Semra Tiryaki Demir, Mine Öztürk, Veysel Levent Karabaş

Zitieren

APA

Demirayak, B., Özkaya, A., Onur, İ. U., Arıcı, M., Korkmaz, A., Özal, E., Ermiş, S., Çiloğlu Hayat, Ş., Karapapak, M., Özal, S. A., Sayın, N., Erdoğan, M., Koçak, İ., Çakır, A., Karataş, G., Yıldız, D., Tokuç, E. Ö., Tiryaki Demir, S., Karataş, M. E., …, & Karabaş, V. L. (2026). Real-world evaluation of anti-VEGF therapy in diabetic macular edema: The role of macular ischemia and OCT biomarkers BOSPHORUS DME study group report no: 14. European Journal of Ophthalmology. https://doi.org/10.1177/11206721261471302

Vancouver

Demirayak B, Özkaya A, Onur İU, Arıcı M, Korkmaz A, Özal E, et al. Real-world evaluation of anti-VEGF therapy in diabetic macular edema: The role of macular ischemia and OCT biomarkers BOSPHORUS DME study group report no: 14. European Journal of Ophthalmology. 2026. doi:10.1177/11206721261471302

BibTeX
@article{Demirayak2026,
  author = {Demirayak, Bengi and Özkaya, Abdullah and Onur, İsmail Umut and Arıcı, Murat and Korkmaz, Anıl and Özal, Ece and Ermiş, Serhat and Çiloğlu Hayat, Şerife and Karapapak, Murat and Özal, Sadık Altan and Sayın, Nihat and Erdoğan, Mehmet and Koçak, İbrahim and Çakır, Akin and Karataş, Gamze and Yıldız, Dilan and Tokuç, Ecem Önder and Tiryaki Demir, Semra and Karataş, Mehmet Egemen and Uçak, Turgay and Hepokur, Mustafa and Öztürk, Mine and Karabaş, Veysel Levent},
  title = {Real-world evaluation of anti-VEGF therapy in diabetic macular edema: The role of macular ischemia and OCT biomarkers BOSPHORUS DME study group report no: 14},
  journal = {European Journal of Ophthalmology},
  year = {2026},
  doi = {10.1177/11206721261471302}
}
Kostenlos starten →